EXTEND DISEASE-FREE SURVIVAL

WITH THE FIRST AND ONLY ADJUVANT TARGETED TREATMENT FOR ALK+ NSCLC1,2

DFS data

ALECENSA significantly reduced the risk of disease recurrence or death by 76% compared 
with platinum-based chemotherapy2

OS data were not mature at the time of the primary DFS analysis with 2.3% of deaths reported overall2

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

*Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2

 

AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NE: not estimable; NSCLC: non-small cell lung cancer; OS: overall survival; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276.

DFS analyses according to disease stage

ALECENSA provided CONSISTENT DFS BENEFIT across Stage IB through to Stage IIIA2,*

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

*These subgroup analyses are exploratory and not powered to demonstrate statistical significance between treatment arms and should therefore be interpreted with caution. Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7th edition of the UICC/AJCC.2

 

AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276.

CNS-DFS data
brain-icon.svg

Patients with ALK+ NSCLC are at high risk for brain metastases, which are associated with poor prognosis and have a substantial effect on health-related quality of life2

ALECENSA provides a 78% reduction in risk of CNS recurrence or death compared with platinum-based chemotherapy2,*

Discover

ALECENSA IN

ALK+ RESECTED NSCLC

*This analysis is exploratory and not powered to demonstrate statistical significance between treatment arms and should therefore be interpreted with caution. Stage IB (tumours ≥4 cm), II or IIIA NSCLC classified according to the 7 edition of the UICC/AJCC.2

 

AJCC: American Joint Committee on Cancer; ALK: anaplastic lymphoma kinase; CI: confidence interval; CNS: central nervous system; DFS: disease-free survival; HR: hazard ratio; ITT: intention-to-treat; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics; UICC: Union for International Cancer Control.


1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2024. Available here (accessed July 2024); 2. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 3. Solomon BJ, et al. Presented at the European Society for Medical Oncology Congress, 20–24 October 2023, Madrid, Spain.